<author><surname>Launay-Vacher</surname> <given-names>V</given-names> </author><author><surname>Deray</surname> <given-names>G</given-names> </author><title>Hypertension and proteinuria: a class-effect of antiangiogenic therapies</title><source>Anticancer Drugs.</source><year>2009</year><volume>20</volume><issue>1</issue><fpage>81</fpage><lpage>82</lpage>
<author><surname>Chowdhury</surname> <given-names>S</given-names> </author><author><surname>Spicer</surname> <given-names>J</given-names> </author><author><surname>Harper</surname> <given-names>P</given-names> </author><title>Hypertension and targeted therapy: part 1. Bevacizumab</title><source>Targeted Oncology.</source><year>2006</year><volume>1</volume><issue>2</issue><fpage>104</fpage><lpage>108</lpage>
<author><surname>Chowdhury</surname> <given-names>S</given-names> </author><author><surname>Spicer</surname> <given-names>J</given-names> </author><author><surname>Harper</surname> <given-names>P</given-names> </author><title>Hypertension and targeted therapy: part 2. Small molecule inhibitors of VEGF</title><source>Targeted Oncology.</source><year>2006</year><volume>1</volume><issue>3</issue><fpage>172</fpage><lpage>178</lpage>
<author><surname>Roodhart</surname> <given-names>JM</given-names> </author><author><surname>Langenberg</surname> <given-names>MH</given-names> </author><author><surname>Witteveen</surname> <given-names>E</given-names> </author><title>The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway</title><source>Curr Clin Pharmacol.</source><year>2008</year><volume>3</volume><issue>2</issue><fpage>132</fpage><lpage>143</lpage>
<author><surname>Humphreys</surname> <given-names>BD</given-names> </author><author><surname>Atkins</surname> <given-names>MB</given-names> </author><title>Rapid development of hypertension by sorafenib: toxicity or target?</title><source>Clin Cancer Res.</source><year>2009</year><volume>15</volume><issue>19</issue><fpage>5947</fpage><lpage>5949</lpage>
<author><surname>Rixe</surname> <given-names>O</given-names> </author><author><surname>Billemont</surname> <given-names>B</given-names> </author><author><surname>Izzedine</surname> <given-names>H</given-names> </author><title>Hypertension as a predictive factor of sunitinib activity</title><source>Ann Oncol.</source><year>2007</year><volume>18</volume><issue>6</issue><fpage>1117</fpage>
<author><surname>Yang</surname> <given-names>R</given-names> </author><author><surname>Thomas</surname> <given-names>GR</given-names> </author><author><surname>Bunting</surname> <given-names>S</given-names> </author><title>Effects of vascular endothelial growth factor on hemodynamics and cardiac performance</title><source>J Cardiovasc Pharmacol.</source><year>1996</year><volume>27</volume><issue>6</issue><fpage>838</fpage><lpage>844</lpage>
<author><surname>Wei</surname> <given-names>W</given-names> </author><author><surname>Jin</surname> <given-names>H</given-names> </author><author><surname>Chen</surname> <given-names>ZW</given-names> </author><title>Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants</title><source>J Cardiovasc Pharmacol.</source><year>2004</year><volume>44</volume><issue>5</issue><fpage>615</fpage><lpage>621</lpage>
<author><surname>Steeghs</surname> <given-names>N</given-names> </author><author><surname>Gelderblom</surname> <given-names>H</given-names> </author><author><surname>Roodt</surname> <given-names>JO</given-names> </author><title>Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor</title><source>Clin Cancer Res.</source><year>2008</year><volume>14</volume><issue>11</issue><fpage>3470</fpage><lpage>3476</lpage>
<author><surname>Dechend</surname> <given-names>R</given-names> </author><author><surname>Luft</surname> <given-names>FC</given-names> </author><title>Angiogenesis factors and preeclampsia</title><source>Nature Med.</source><year>2008</year><volume>14</volume><issue>11</issue><fpage>1187</fpage><lpage>1188</lpage>
<author><surname>Motzer</surname> <given-names>RJ</given-names> </author><author><surname>Hutson</surname> <given-names>TE</given-names> </author><author><surname>Tomczak</surname> <given-names>P</given-names> </author><title>Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma</title><source>J Clin Oncol.</source><year>2009</year><volume>27</volume><issue>22</issue><fpage>3584</fpage><lpage>3590</lpage>
<title>Sunitinib malate (SUTENT&#174;) prescribing information. Revised July 2010</title>
<author><surname>Rini</surname> <given-names>BI</given-names> </author><author><surname>Schiller</surname> <given-names>JH</given-names> </author><author><surname>Fruehauf</surname> <given-names>JP</given-names> </author>Association of diastolic blood pressure (dBP) &gt;= 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). Poster presentation at the 44th annual meeting of the American Society of Clinical Oncology. Chicago, IL. May 30, 2008 to June 3, 2008. Abstract 3543
<author><surname>Bono</surname> <given-names>P</given-names> </author><author><surname>Elfving</surname> <given-names>H</given-names> </author><author><surname>Utriainen</surname> <given-names>T</given-names> </author><title>Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma</title><source>Ann Oncol.</source><year>2009</year><volume>20</volume><issue>2</issue><fpage>393</fpage><lpage>394</lpage>
<author><surname>Dahlberg</surname> <given-names>SE</given-names> </author><author><surname>Sandler</surname> <given-names>AB</given-names> </author><author><surname>Brahmer</surname> <given-names>JR</given-names> </author><author><surname>Schiller</surname> <given-names>JH</given-names> </author><author><surname>Johnson</surname> <given-names>DH</given-names> </author><title>Clinical course of advanced non&#8211;small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599</title><source>J Clin Oncol.</source><year>2010</year><volume>28</volume><issue>6</issue><fpage>949</fpage><lpage>954</lpage>
<author><surname>Friberg</surname> <given-names>G</given-names> </author><author><surname>Kasza</surname> <given-names>K</given-names> </author><author><surname>Vokes</surname> <given-names>EE</given-names> </author><title>Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G)</title><source>J Clin Oncol.</source><year>2005</year><volume>23</volume><issue>suppl</issue><fpage>196s</fpage>Abstract 3020
<author><surname>Scartozzi</surname> <given-names>M</given-names> </author><author><surname>Galizia</surname> <given-names>E</given-names> </author><author><surname>Chiorrini</surname> <given-names>S</given-names> </author><title>Arterial hypertension correlates with clinical outcome in colorectal cancer patients with first-line bevacizumab</title><source>Ann Oncol.</source><year>2009</year><volume>20</volume><issue>2</issue><fpage>227</fpage><lpage>230</lpage>
<author><surname>Gore</surname> <given-names>ME</given-names> </author><author><surname>Szczylik</surname> <given-names>C</given-names> </author><author><surname>Porta</surname> <given-names>C</given-names> </author><title>Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial</title><source>Lancet Oncol.</source><year>2009</year><volume>10</volume><issue>8</issue><fpage>757</fpage><lpage>763</lpage>
<author><surname>Motzer</surname> <given-names>RJ</given-names> </author><author><surname>Michaelson</surname> <given-names>MD</given-names> </author><author><surname>Redman</surname> <given-names>BG</given-names> </author><title>Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma</title><source>J Clin Oncol.</source><year>2006</year><volume>24</volume><issue>1</issue><fpage>16</fpage><lpage>24</lpage>
<author><surname>Motzer</surname> <given-names>RJ</given-names> </author><author><surname>Rini</surname> <given-names>BI</given-names> </author><author><surname>Bukowski</surname> <given-names>RM</given-names> </author><title>Sunitinib in patients with metastatic renal cell carcinoma</title><source>JAMA.</source><year>2006</year><volume>295</volume><issue>21</issue><fpage>2516</fpage><lpage>2524</lpage>
<author><surname>Motzer</surname> <given-names>RJ</given-names> </author><author><surname>Hutson</surname> <given-names>TE</given-names> </author><author><surname>Tomczak</surname> <given-names>P</given-names> </author><title>Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</title><source>N Engl J Med.</source><year>2007</year><volume>356</volume><issue>2</issue><fpage>115</fpage><lpage>124</lpage>
<author><surname>Therasse</surname> <given-names>P</given-names> </author><author><surname>Arbuck</surname> <given-names>SG</given-names> </author><author><surname>Eisenhauer</surname> <given-names>EA</given-names> </author><title>New guidelines to evaluate the response to treatment in solid tumors</title><source>J Natl Cancer Inst.</source><year>2000</year><volume>92</volume><issue>3</issue><fpage>205</fpage><lpage>216</lpage>
<author><surname>Chobanian</surname> <given-names>AV</given-names> </author><author><surname>Bakris</surname> <given-names>GL</given-names> </author><author><surname>Black</surname> <given-names>HR</given-names> </author><title>Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</title><source>Hypertension.</source><year>2003</year><volume>42</volume><issue>6</issue><fpage>1206</fpage><lpage>1252</lpage>
<author><surname>Motzer</surname> <given-names>RJ</given-names> </author><author><surname>Bacik</surname> <given-names>J</given-names> </author><author><surname>Murphy</surname> <given-names>BA</given-names> </author><title>Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma</title><source>J Clin Oncol.</source><year>2002</year><volume>20</volume><issue>1</issue><fpage>289</fpage><lpage>296</lpage>
<author><surname>Heng</surname> <given-names>DY</given-names> </author><author><surname>Xie</surname> <given-names>W</given-names> </author><author><surname>Regan</surname> <given-names>MM</given-names> </author><title>Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study</title><source>J Clin Oncol.</source><year>2009</year><volume>27</volume><issue>34</issue><fpage>5794</fpage><lpage>5799</lpage>
<author><surname>Zhu</surname> <given-names>X</given-names> </author><author><surname>Stergiopoulos</surname> <given-names>K</given-names> </author><author><surname>Wu</surname> <given-names>S</given-names> </author><title>Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis</title><source>Acta Oncol.</source><year>2009</year><volume>48</volume><issue>1</issue><fpage>9</fpage><lpage>17</lpage>
<author><surname>Launay-Vacher</surname> <given-names>V</given-names> </author><author><surname>Ayllon</surname> <given-names>J</given-names> </author><author><surname>Janus</surname> <given-names>N</given-names> </author><title>Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma [published online ahead of print November 12, 2009]</title><source>Urol Oncol</source>
<author><surname>Maitland</surname> <given-names>ML</given-names> </author><author><surname>Bakris</surname> <given-names>GL</given-names> </author><author><surname>Black</surname> <given-names>HR</given-names> </author><title>Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors</title><source>J Natl Cancer Inst.</source><year>2010</year><volume>102</volume><issue>9</issue><fpage>596</fpage><lpage>604</lpage>
<author><surname>Langenberg</surname> <given-names>MH</given-names> </author><author><surname>van Herpen</surname> <given-names>CM</given-names> </author><author><surname>De Bono</surname> <given-names>J</given-names> </author><title>Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors</title><source>J Clin Oncol.</source><year>2009</year><volume>27</volume><issue>36</issue><fpage>6152</fpage><lpage>6159</lpage>
<author><surname>Bamias</surname> <given-names>A</given-names> </author><author><surname>Lainakis</surname> <given-names>G</given-names> </author><author><surname>Manios</surname> <given-names>E</given-names> </author><title>Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib</title><source>J Chemother.</source><year>2009</year><volume>21</volume><issue>3</issue><fpage>347</fpage><lpage>350</lpage>
<author><surname>Van Heeckeren</surname> <given-names>WJ</given-names> </author><author><surname>Ortiz</surname> <given-names>J</given-names> </author><author><surname>Cooney</surname> <given-names>MM</given-names> </author><title>Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?</title><source>J Clin Oncol.</source><year>2007</year><volume>25</volume><issue>21</issue><fpage>2993</fpage><lpage>2995</lpage>
<author><surname>Hood</surname> <given-names>JD</given-names> </author><author><surname>Meininger</surname> <given-names>CJ</given-names> </author><author><surname>Ziche</surname> <given-names>M</given-names> </author><title>VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells</title><source>Am J Physiol.</source><year>1998</year><volume>274</volume><issue>3, pt 2</issue><fpage>H1054</fpage><lpage>H1058</lpage>
<author><surname>van der Veldt</surname> <given-names>AA</given-names> </author><author><surname>de Boer</surname> <given-names>MP</given-names> </author><author><surname>Boven</surname> <given-names>E</given-names> </author><title>Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib</title><source>Anticancer Drugs.</source><year>2010</year><volume>21</volume><issue>4</issue><fpage>439</fpage><lpage>446</lpage>
<author><surname>Houk</surname> <given-names>BE</given-names> </author><author><surname>Bello</surname> <given-names>CL</given-names> </author><author><surname>Poland</surname> <given-names>B</given-names> </author><author><surname>Rosen</surname> <given-names>LS</given-names> </author><author><surname>Demetri</surname> <given-names>GD</given-names> </author><author><surname>Motzer</surname> <given-names>RJ</given-names> </author><title>Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis</title><source>Cancer Chemother Pharmacol.</source><year>2010</year><volume>66</volume><issue>2</issue><fpage>357</fpage><lpage>371</lpage>